Is Lobrena always the first-line choice for ALK mutation at 47?

Question

Hello doctor,

I am 47 and recently diagnosed with lung cancer; the biopsy showed an ALK mutation on report. A PET scan shows spread to the lungs and a few lymph nodes; a brain MRI is clear for now.

My oncologist suggested starting Lobrena straight away, but when I read on the internet, I saw other ALK drugs like Alectinib and Crizotinib used earlier. That confused me.

So, I am looking for your opinions on the following:

Is Lobrena always the first line for ALK mutation at 47?
Does starting with a stronger drug give better long-term control or reduce future options?
Also, I am worried about side effects like memory issues and mood changes. Should treatment choice depend on the spread pattern or mutation type?

Kindly suggest.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

I have read your query and understand your concern.

I understand why you feel confused after reading about different medicines on the internet. When lung cancer shows an ALK (anaplastic lymphoma kinase) mutation, it means the cancer cells are driven by a specific abnormal protein.

Certain medicines called ALK inhibitors are designed to block this signal and can control the cancer very effectively in many patients. Several ALK inhibitors are available, including Crizotinib, Alectinib, Brigatinib, and Lorlatinib (Lorbrena).

These drugs were developed over time, and the newer ones generally control the disease for longer and also work better in preventing or treating spread to the brain.

In the past, Crizotinib was commonly used first, but with more research, many oncologists now prefer newer medicines such as Alectinib or sometimes Lorlatinib as the initial treatment.

Starting with Lorlatinib is therefore not unusual. It is considered a very potent ALK inhibitor and, in some studies, has shown strong and durable disease control.

Some oncologists prefer to use it earlier, especially in younger patients or when they want the strongest possible control of the disease from the beginning.

Other doctors may start with Alectinib and keep Lorlatinib as a later option if the cancer eventually develops resistance. Both strategies are used in practice, and the choice often depends on the treating oncologist’s judgement and the patient’s individual situation.

Regarding side effects, Lorlatinib can sometimes cause effects related to the nervous system, such as mild changes in memory, concentration, mood, or sleep. Not everyone experiences these problems, and when they occur, they are usually manageable with dose adjustment or supportive care.

Doctors also monitor blood tests because this medicine can raise cholesterol or triglyceride levels. If you notice clear changes in mood, confusion, significant memory issues, or unusual behaviour, you should inform your oncology team promptly.

The treatment decision is not based only on the mutation itself but also on factors such as the pattern of spread, overall health, and the need for good brain protection.

Even though your brain MRI (magnetic resonance imaging) is currently clear, many ALK inhibitors are chosen partly because they can also prevent future brain metastasis, which is a known risk in ALK-positive lung cancer.

I hope I have addressed all of your queries and concerns.

Do follow up for more queries.

Thank you.